Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study

Lisa Bodei, Marta Cremonesi, Chiara M. Grana, Nicola Fazio, Simona Iodice, Silvia M. Baio, Mirco Bartolomei, Dario Lombardo, Mahila E. Ferrari, Maddalena Sansovini, Marco Chinol, Giovanni Paganelli

Research output: Contribution to journalArticle

Abstract

Purpose: Peptide receptor radionuclide therapy (PRRT) is used in tumours expressing type 2 somatostatin receptors (sst 2), mainly neuroendocrine. The aim of this prospective phase I-II study was to evaluate the toxicity and efficacy of 177Lu-DOTATATE in multiple cycles. Methods: Fifty-one consecutive patients with unresectable/metastatic sst 2-positive tumours, divided into two groups, received escalating activities (3.7-5.18 GBq/cycle, group 1; 5.18-7.4 GBq/cycle, group 2) of 177Lu-DOTATATE. Cumulative activities ranged from 3.7 to 29.2 GBq (median 26.4 GBq in median 6 cycles, group 1, 21 patients) and 5.55 to 28.9 GBq (median 25.2 GBq in 4 cycles, group 2, 30 patients), based on dosimetry. Results: No major acute or delayed renal or haematological toxicity occurred (one grade 3 leukopenia and thrombocytopenia). Cumulative renal absorbed doses were 8-37 Gy (9-41 Gy bioeffective doses). A median decrease of creatinine clearance of 21.7% 6 months after PRRT, 23.9% after 1 year and 27.6% after 2 years was observed. Higher losses (>20%) occurred in patients with risk factors for renal toxicity, particularly hypertension and diabetes. Cumulative bone marrow doses were 177Lu-DOTATATE was well tolerated up to 29 GBq cumulative activity (up to 7.4 GBq/cycle). The maximum tolerated dose/cycle was not reached. However, considering the individual bone marrow function and the presence of risk factors for kidney toxicity, it seems safer to divide cumulative activities into lower activity cycles.

Original languageEnglish
Pages (from-to)2125-2135
Number of pages11
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume38
Issue number12
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Peptide Receptors
Radioisotopes
Kidney
Bone Marrow
Activity Cycles
Maximum Tolerated Dose
Leukopenia
Therapeutics
Creatinine
Neoplasms
Hypertension
(177lutetium-DOTA(O)Tyr3)octreotate

Keywords

  • Lu-DOTATATE
  • Neuroendocrine tumours
  • Peptide receptor radionuclide therapy
  • Phase I-II
  • PRRT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Peptide receptor radionuclide therapy with 177Lu-DOTATATE : The IEO phase I-II study. / Bodei, Lisa; Cremonesi, Marta; Grana, Chiara M.; Fazio, Nicola; Iodice, Simona; Baio, Silvia M.; Bartolomei, Mirco; Lombardo, Dario; Ferrari, Mahila E.; Sansovini, Maddalena; Chinol, Marco; Paganelli, Giovanni.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, No. 12, 12.2011, p. 2125-2135.

Research output: Contribution to journalArticle

@article{7bdabfb861824751ad9d4c7bac08d5af,
title = "Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study",
abstract = "Purpose: Peptide receptor radionuclide therapy (PRRT) is used in tumours expressing type 2 somatostatin receptors (sst 2), mainly neuroendocrine. The aim of this prospective phase I-II study was to evaluate the toxicity and efficacy of 177Lu-DOTATATE in multiple cycles. Methods: Fifty-one consecutive patients with unresectable/metastatic sst 2-positive tumours, divided into two groups, received escalating activities (3.7-5.18 GBq/cycle, group 1; 5.18-7.4 GBq/cycle, group 2) of 177Lu-DOTATATE. Cumulative activities ranged from 3.7 to 29.2 GBq (median 26.4 GBq in median 6 cycles, group 1, 21 patients) and 5.55 to 28.9 GBq (median 25.2 GBq in 4 cycles, group 2, 30 patients), based on dosimetry. Results: No major acute or delayed renal or haematological toxicity occurred (one grade 3 leukopenia and thrombocytopenia). Cumulative renal absorbed doses were 8-37 Gy (9-41 Gy bioeffective doses). A median decrease of creatinine clearance of 21.7{\%} 6 months after PRRT, 23.9{\%} after 1 year and 27.6{\%} after 2 years was observed. Higher losses (>20{\%}) occurred in patients with risk factors for renal toxicity, particularly hypertension and diabetes. Cumulative bone marrow doses were 177Lu-DOTATATE was well tolerated up to 29 GBq cumulative activity (up to 7.4 GBq/cycle). The maximum tolerated dose/cycle was not reached. However, considering the individual bone marrow function and the presence of risk factors for kidney toxicity, it seems safer to divide cumulative activities into lower activity cycles.",
keywords = "Lu-DOTATATE, Neuroendocrine tumours, Peptide receptor radionuclide therapy, Phase I-II, PRRT",
author = "Lisa Bodei and Marta Cremonesi and Grana, {Chiara M.} and Nicola Fazio and Simona Iodice and Baio, {Silvia M.} and Mirco Bartolomei and Dario Lombardo and Ferrari, {Mahila E.} and Maddalena Sansovini and Marco Chinol and Giovanni Paganelli",
year = "2011",
month = "12",
doi = "10.1007/s00259-011-1902-1",
language = "English",
volume = "38",
pages = "2125--2135",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "12",

}

TY - JOUR

T1 - Peptide receptor radionuclide therapy with 177Lu-DOTATATE

T2 - The IEO phase I-II study

AU - Bodei, Lisa

AU - Cremonesi, Marta

AU - Grana, Chiara M.

AU - Fazio, Nicola

AU - Iodice, Simona

AU - Baio, Silvia M.

AU - Bartolomei, Mirco

AU - Lombardo, Dario

AU - Ferrari, Mahila E.

AU - Sansovini, Maddalena

AU - Chinol, Marco

AU - Paganelli, Giovanni

PY - 2011/12

Y1 - 2011/12

N2 - Purpose: Peptide receptor radionuclide therapy (PRRT) is used in tumours expressing type 2 somatostatin receptors (sst 2), mainly neuroendocrine. The aim of this prospective phase I-II study was to evaluate the toxicity and efficacy of 177Lu-DOTATATE in multiple cycles. Methods: Fifty-one consecutive patients with unresectable/metastatic sst 2-positive tumours, divided into two groups, received escalating activities (3.7-5.18 GBq/cycle, group 1; 5.18-7.4 GBq/cycle, group 2) of 177Lu-DOTATATE. Cumulative activities ranged from 3.7 to 29.2 GBq (median 26.4 GBq in median 6 cycles, group 1, 21 patients) and 5.55 to 28.9 GBq (median 25.2 GBq in 4 cycles, group 2, 30 patients), based on dosimetry. Results: No major acute or delayed renal or haematological toxicity occurred (one grade 3 leukopenia and thrombocytopenia). Cumulative renal absorbed doses were 8-37 Gy (9-41 Gy bioeffective doses). A median decrease of creatinine clearance of 21.7% 6 months after PRRT, 23.9% after 1 year and 27.6% after 2 years was observed. Higher losses (>20%) occurred in patients with risk factors for renal toxicity, particularly hypertension and diabetes. Cumulative bone marrow doses were 177Lu-DOTATATE was well tolerated up to 29 GBq cumulative activity (up to 7.4 GBq/cycle). The maximum tolerated dose/cycle was not reached. However, considering the individual bone marrow function and the presence of risk factors for kidney toxicity, it seems safer to divide cumulative activities into lower activity cycles.

AB - Purpose: Peptide receptor radionuclide therapy (PRRT) is used in tumours expressing type 2 somatostatin receptors (sst 2), mainly neuroendocrine. The aim of this prospective phase I-II study was to evaluate the toxicity and efficacy of 177Lu-DOTATATE in multiple cycles. Methods: Fifty-one consecutive patients with unresectable/metastatic sst 2-positive tumours, divided into two groups, received escalating activities (3.7-5.18 GBq/cycle, group 1; 5.18-7.4 GBq/cycle, group 2) of 177Lu-DOTATATE. Cumulative activities ranged from 3.7 to 29.2 GBq (median 26.4 GBq in median 6 cycles, group 1, 21 patients) and 5.55 to 28.9 GBq (median 25.2 GBq in 4 cycles, group 2, 30 patients), based on dosimetry. Results: No major acute or delayed renal or haematological toxicity occurred (one grade 3 leukopenia and thrombocytopenia). Cumulative renal absorbed doses were 8-37 Gy (9-41 Gy bioeffective doses). A median decrease of creatinine clearance of 21.7% 6 months after PRRT, 23.9% after 1 year and 27.6% after 2 years was observed. Higher losses (>20%) occurred in patients with risk factors for renal toxicity, particularly hypertension and diabetes. Cumulative bone marrow doses were 177Lu-DOTATATE was well tolerated up to 29 GBq cumulative activity (up to 7.4 GBq/cycle). The maximum tolerated dose/cycle was not reached. However, considering the individual bone marrow function and the presence of risk factors for kidney toxicity, it seems safer to divide cumulative activities into lower activity cycles.

KW - Lu-DOTATATE

KW - Neuroendocrine tumours

KW - Peptide receptor radionuclide therapy

KW - Phase I-II

KW - PRRT

UR - http://www.scopus.com/inward/record.url?scp=84856222127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856222127&partnerID=8YFLogxK

U2 - 10.1007/s00259-011-1902-1

DO - 10.1007/s00259-011-1902-1

M3 - Article

C2 - 21892623

AN - SCOPUS:84856222127

VL - 38

SP - 2125

EP - 2135

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 12

ER -